Literature DB >> 24909808

Therapeutic modulation of gut microbiota: current clinical applications and future perspectives.

Gianluca Ianiro, Stefano Bibbò, Antonio Gasbarrini, Giovanni Cammarota1.   

Abstract

Human beings and gut microbiota are in a symbiotic relationship, and the hypothesis of a "super organism" composed of the human organism and microbes has been recently proposed. The gut microbiota fulfills important metabolic and immunological tasks, and the impairment of its composition might alter homeostasis and lead to the development of microbiota-related diseases. The most common illnesses associated with alterations of the gut microbiota include inflammatory bowel disease, gastroenteric infections, irritable bowel syndrome and other gastrointestinal functional diseases, colorectal cancer, metabolic syndrome and obesity, liver diseases, allergic diseases, and neurological diseases such as autism. In theory, every disease associated with the impairment of intestinal microflora might benefit from the therapeutic modulation of the gut microbiota. A number of attempts to manipulate the microbiota have not produced identical results for every disease. Although antibiotics and probiotics have been available for a long time, the so-called fecal microbiota transplantation, which is a very old remedy, was only recently re-evaluated as a promising therapeutic approach for microbiota impairment. A comprehensive understanding of the gut microbiota composition, in states of both health and various diseases, is needed for the development of future approaches for microbiota modulation and for developing targeted therapies. In this review, we describe the role of the microbiota in several diseases and the related treatment options that are currently available.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24909808     DOI: 10.2174/1389450115666140606111402

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  33 in total

Review 1.  Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation.

Authors:  Anastasia I Petra; Smaro Panagiotidou; Erifili Hatziagelaki; Julia M Stewart; Pio Conti; Theoharis C Theoharides
Journal:  Clin Ther       Date:  2015-05-01       Impact factor: 3.393

Review 2.  Gut microbiota: a key player in health and disease. A review focused on obesity.

Authors:  M J Villanueva-Millán; P Pérez-Matute; J A Oteo
Journal:  J Physiol Biochem       Date:  2015-03-08       Impact factor: 4.158

Review 3.  Microbiota-based treatments in alcoholic liver disease.

Authors:  Hotaik Sung; Seung Woo Kim; Meegun Hong; Ki Tae Suk
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

Review 4.  Decoding the microbiome for the development of translational applications: Overview, challenges and pitfalls.

Authors:  Mohammed Monzoorul Haque; Sharmila S Mande
Journal:  J Biosci       Date:  2019-10       Impact factor: 1.826

5.  Triclosan and prescription antibiotic exposures and enterolactone production in adults.

Authors:  Margaret A Adgent; Walter J Rogan
Journal:  Environ Res       Date:  2015-06-23       Impact factor: 6.498

Review 6.  Probiotics for people with hepatic encephalopathy.

Authors:  Rohan Dalal; Richard G McGee; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

7.  Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Authors:  Sanjay K Shukla; Dane Cook; Jacob Meyer; Suzanne D Vernon; Thao Le; Derek Clevidence; Charles E Robertson; Steven J Schrodi; Steven Yale; Daniel N Frank
Journal:  PLoS One       Date:  2015-12-18       Impact factor: 3.240

Review 8.  Systemic effects of gut microbiota and its relationship with disease and modulation.

Authors:  Jolie T K Ho; Godfrey C F Chan; James C B Li
Journal:  BMC Immunol       Date:  2015-03-26       Impact factor: 3.615

Review 9.  Alternatives to antibiotics in animal agriculture: an ecoimmunological view.

Authors:  Yongming Sang; Frank Blecha
Journal:  Pathogens       Date:  2014-12-29

10.  Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial.

Authors:  Valentin Mocanu; Zhengxiao Zhang; Edward C Deehan; Dina H Kao; Naomi Hotte; Shahzeer Karmali; Daniel W Birch; Kalutota K Samarasinghe; Jens Walter; Karen L Madsen
Journal:  Nat Med       Date:  2021-07-05       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.